Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Signaling beneath the Cell Surface

This article was originally published in Start Up

Executive Summary

Designing molecules that target protein-protein interactions in transmembrane proteins, where antibodies and fragments cannot penetrate, has been difficult. Using computational methods, a group at Penn has created novel peptides that could offer a new class of reagents for studying membrane-protein folding, assembly, and signal transduction. More broadly, they could provide access to an entire new class of targets for the design of therapeutics and drug delivery systems

You may also be interested in...



PolyMedix Inc.

PolyMedix uses a suite of proprietary, patented computational tools to create simple, easily synthesized organic small molecule compounds that mimic the activity of host defense proteins. The company's first focus is to create antibiotic candidates, and eventually, drugs for cancer and cardiovascular disease. It will seek nearer-term revenues from materials applications of its technologies.

Understanding How To Develop BTK Inhibitors In MS Is Evolving

Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.

Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development

Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel